ZGNX News and Press, Zogenix Inc. From 12/21/21

Zogenix (NASDAQ:ZGNX) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of Fintepla (fenfluramine) for the treatment of epileptic seizures associated with Dravet syndrome. The submission is supported by the re...

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval...

EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agen...

The following slide deck was published by Zogenix, Inc. in conjunction with this event. For further details see: Zogenix (ZGNX) Investor Presentation - Slideshow

EMERYVILLE, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will present new FINTEPLA ® (fenfluramine) data from eight abstracts at the American ...

Applied UV (NASDAQ:AUVI) +47%. Skylight Health Group (NASDAQ:SLHG) +27%. Ardelyx (NASDAQ:ARDX) +18%. IceCure Medical (NASDAQ:ICCM) +17%. Energy Focus (NASDAQ:EFOI) +17%. Ambarella (NASDAQ:AMBA) +15% on Q3 results VBI Vaccines (NASDAQ:VBIV) +14% wins FDA approval for Hepatitis B vacc...

Zogenix (NASDAQ:ZGNX) perks up 7.3% premarket following an announcement that the FDA has accepted for filing and granted Priority Review to its supplemental New Drug Application (sNDA) for the use of Fintepla for the treatment of seizures associated with Lennox-Gastau...

EMERYVILLE, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the company’s sup...

Zogenix, Inc. (ZGNX) Q3 2021 Earnings Conference Call November 4, 2021, 04:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Stephen Farr - Co-Founder, CEO, President & Director Ashish Sagrolikar - EVP & Chief Commercial Officer Michael Smith - EVP, CFO & Treasure...

Zogenix (NASDAQ:ZGNX): Q3 GAAP EPS of $1.04 beats by $2.02. Revenue of $22.6M (+690.2% Y/Y) misses by $0.11M. Press Release For further details see: Zogenix EPS beats by $2.02, misses on revenue